Texas Heart Institute
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1962-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.texasheart.org
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Pomegranate Products for Prevention of Common Cold
- Conditions
- InfluenzaCoughFeverCommon ColdHeadache
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2008-02-18
- Lead Sponsor
- Texas Heart Institute
- Target Recruit Count
- 461
- Registration Number
- NCT00617318
- Locations
- 🇺🇸
Site 01, San Diego, California, United States
Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2006-04-13
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Texas Heart Institute
- Target Recruit Count
- 21
- Registration Number
- NCT00314366
- Locations
- 🇺🇸
Texas Heart Institute/Baylor St. Luke's Medical Center, Houston, Texas, United States
Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)
- Conditions
- Ischemic Cardiomyopathy
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Texas Heart Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00203203
- Locations
- 🇺🇸
Texas Heart Institute/Baylor St. Luke's Medical Center, Houston, Texas, United States
News
FDA Approves Phase 2 Trial of Revolutionary BiVACOR Artificial Heart Device
• The FDA has authorized Phase 2 clinical trials for the BiVACOR mechanical heart, allowing 15 additional patients to receive the device and recover at home while awaiting donor hearts. • The innovative BiVACOR device features a single moving part - a magnetically suspended spinning disc - potentially offering a more durable and permanent alternative to traditional heart transplants. • The first human recipient, Batson Avie, experienced immediate improvement after implantation at Texas Heart Institute, demonstrating the device's promising potential for treating advanced heart failure.
Email Reminders Boost Flu Shot Rates in Post-MI Patients, Especially with CV-Focused Messaging
A pooled analysis of the NUDGE-FLU trials shows email reminders increase flu vaccination rates among patients with a history of acute myocardial infarction.